Global Monoclonal Antibody Drugs for Cancer Supply, Demand and Key Producers, 2023-2029
The global Monoclonal Antibody Drugs for Cancer market size is expected to reach $ 155030 million by 2029, rising at a market growth of 8.1% CAGR during the forecast period (2023-2029).
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
This report studies the global Monoclonal Antibody Drugs for Cancer demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Monoclonal Antibody Drugs for Cancer, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Monoclonal Antibody Drugs for Cancer that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Monoclonal Antibody Drugs for Cancer total market, 2018-2029, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Monoclonal Antibody Drugs for Cancer total market, key domestic companies and share, (USD Million)
Global Monoclonal Antibody Drugs for Cancer revenue by player and market share 2018-2023, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by Type, CAGR, 2018-2029, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Monoclonal Antibody Drugs for Cancer market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co and Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Monoclonal Antibody Drugs for Cancer market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Monoclonal Antibody Drugs for Cancer Market, By Region:
1. How big is the global Monoclonal Antibody Drugs for Cancer market?
2. What is the demand of the global Monoclonal Antibody Drugs for Cancer market?
3. What is the year over year growth of the global Monoclonal Antibody Drugs for Cancer market?
4. What is the total value of the global Monoclonal Antibody Drugs for Cancer market?
5. Who are the major players in the global Monoclonal Antibody Drugs for Cancer market?
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
This report studies the global Monoclonal Antibody Drugs for Cancer demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Monoclonal Antibody Drugs for Cancer, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Monoclonal Antibody Drugs for Cancer that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Monoclonal Antibody Drugs for Cancer total market, 2018-2029, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Monoclonal Antibody Drugs for Cancer total market, key domestic companies and share, (USD Million)
Global Monoclonal Antibody Drugs for Cancer revenue by player and market share 2018-2023, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by Type, CAGR, 2018-2029, (USD Million)
Global Monoclonal Antibody Drugs for Cancer total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Monoclonal Antibody Drugs for Cancer market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co and Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Monoclonal Antibody Drugs for Cancer market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Monoclonal Antibody Drugs for Cancer Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Mouse-derived Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Blood-related Cancer
- Other
- Johnson & Johnson
- Novartis
- Gilead Sciences
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Merck & Co
- Takeda
- Merck KGaA
- Seagen
- Eli Lilly
- Ono Pharmaceutical
- Pfizer
- Regeneron
- Innovent
- Hengrui Medicine
1. How big is the global Monoclonal Antibody Drugs for Cancer market?
2. What is the demand of the global Monoclonal Antibody Drugs for Cancer market?
3. What is the year over year growth of the global Monoclonal Antibody Drugs for Cancer market?
4. What is the total value of the global Monoclonal Antibody Drugs for Cancer market?
5. Who are the major players in the global Monoclonal Antibody Drugs for Cancer market?
1 SUPPLY SUMMARY
1.1 Monoclonal Antibody Drugs for Cancer Introduction
1.2 World Monoclonal Antibody Drugs for Cancer Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Monoclonal Antibody Drugs for Cancer Total Market by Region (by Headquarter Location)
1.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.3 China Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.4 Europe Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.5 Japan Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.6 South Korea Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.7 ASEAN Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.8 India Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Monoclonal Antibody Drugs for Cancer Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Monoclonal Antibody Drugs for Cancer Major Market Trends
2 DEMAND SUMMARY
2.1 World Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.2 World Monoclonal Antibody Drugs for Cancer Consumption Value by Region
2.2.1 World Monoclonal Antibody Drugs for Cancer Consumption Value by Region (2018-2023)
2.2.2 World Monoclonal Antibody Drugs for Cancer Consumption Value Forecast by Region (2024-2029)
2.3 United States Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.4 China Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.5 Europe Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.6 Japan Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.7 South Korea Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.8 ASEAN Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.9 India Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
3 WORLD MONOCLONAL ANTIBODY DRUGS FOR CANCER COMPANIES COMPETITIVE ANALYSIS
3.1 World Monoclonal Antibody Drugs for Cancer Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Monoclonal Antibody Drugs for Cancer Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Monoclonal Antibody Drugs for Cancer in 2022
3.2.3 Global Concentration Ratios (CR8) for Monoclonal Antibody Drugs for Cancer in 2022
3.3 Monoclonal Antibody Drugs for Cancer Company Evaluation Quadrant
3.4 Monoclonal Antibody Drugs for Cancer Market: Overall Company Footprint Analysis
3.4.1 Monoclonal Antibody Drugs for Cancer Market: Region Footprint
3.4.2 Monoclonal Antibody Drugs for Cancer Market: Company Product Type Footprint
3.4.3 Monoclonal Antibody Drugs for Cancer Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Monoclonal Antibody Drugs for Cancer Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Monoclonal Antibody Drugs for Cancer Consumption Value Comparison
4.2.1 United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Monoclonal Antibody Drugs for Cancer Companies and Market Share, 2018-2023
4.3.1 United States Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
4.4 China Based Companies Monoclonal Antibody Drugs for Cancer Revenue and Market Share, 2018-2023
4.4.1 China Based Monoclonal Antibody Drugs for Cancer Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
4.5 Rest of World Based Monoclonal Antibody Drugs for Cancer Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Monoclonal Antibody Drugs for Cancer Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Mouse-derived Antibodies
5.2.2 Chimeric Antibodies
5.2.3 Humanized Antibodies
5.3 Market Segment by Type
5.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Type (2018-2023)
5.3.2 World Monoclonal Antibody Drugs for Cancer Market Size by Type (2024-2029)
5.3.3 World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Monoclonal Antibody Drugs for Cancer Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Lung Cancer
6.2.2 Breast Cancer
6.2.3 Prostate Cancer
6.2.4 Blood-related Cancer
6.2.5 Blood-related Cancer
6.3 Market Segment by Application
6.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2023)
6.3.2 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2024-2029)
6.3.3 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Details
7.1.2 Johnson & Johnson Major Business
7.1.3 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product and Services
7.1.4 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Johnson & Johnson Recent Developments/Updates
7.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Monoclonal Antibody Drugs for Cancer Product and Services
7.2.4 Novartis Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Gilead Sciences
7.3.1 Gilead Sciences Details
7.3.2 Gilead Sciences Major Business
7.3.3 Gilead Sciences Monoclonal Antibody Drugs for Cancer Product and Services
7.3.4 Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Gilead Sciences Recent Developments/Updates
7.3.6 Gilead Sciences Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche Monoclonal Antibody Drugs for Cancer Product and Services
7.4.4 Roche Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Details
7.5.2 Bristol-Myers Squibb Major Business
7.5.3 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product and Services
7.5.4 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bristol-Myers Squibb Recent Developments/Updates
7.5.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.6 Amgen
7.6.1 Amgen Details
7.6.2 Amgen Major Business
7.6.3 Amgen Monoclonal Antibody Drugs for Cancer Product and Services
7.6.4 Amgen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Amgen Recent Developments/Updates
7.6.6 Amgen Competitive Strengths & Weaknesses
7.7 AstraZeneca
7.7.1 AstraZeneca Details
7.7.2 AstraZeneca Major Business
7.7.3 AstraZeneca Monoclonal Antibody Drugs for Cancer Product and Services
7.7.4 AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 AstraZeneca Recent Developments/Updates
7.7.6 AstraZeneca Competitive Strengths & Weaknesses
7.8 Merck & Co
7.8.1 Merck & Co Details
7.8.2 Merck & Co Major Business
7.8.3 Merck & Co Monoclonal Antibody Drugs for Cancer Product and Services
7.8.4 Merck & Co Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Merck & Co Recent Developments/Updates
7.8.6 Merck & Co Competitive Strengths & Weaknesses
7.9 Takeda
7.9.1 Takeda Details
7.9.2 Takeda Major Business
7.9.3 Takeda Monoclonal Antibody Drugs for Cancer Product and Services
7.9.4 Takeda Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Takeda Recent Developments/Updates
7.9.6 Takeda Competitive Strengths & Weaknesses
7.10 Merck KGaA
7.10.1 Merck KGaA Details
7.10.2 Merck KGaA Major Business
7.10.3 Merck KGaA Monoclonal Antibody Drugs for Cancer Product and Services
7.10.4 Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Merck KGaA Recent Developments/Updates
7.10.6 Merck KGaA Competitive Strengths & Weaknesses
7.11 Seagen
7.11.1 Seagen Details
7.11.2 Seagen Major Business
7.11.3 Seagen Monoclonal Antibody Drugs for Cancer Product and Services
7.11.4 Seagen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Seagen Recent Developments/Updates
7.11.6 Seagen Competitive Strengths & Weaknesses
7.12 Eli Lilly
7.12.1 Eli Lilly Details
7.12.2 Eli Lilly Major Business
7.12.3 Eli Lilly Monoclonal Antibody Drugs for Cancer Product and Services
7.12.4 Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Eli Lilly Recent Developments/Updates
7.12.6 Eli Lilly Competitive Strengths & Weaknesses
7.13 Ono Pharmaceutical
7.13.1 Ono Pharmaceutical Details
7.13.2 Ono Pharmaceutical Major Business
7.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product and Services
7.13.4 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Ono Pharmaceutical Recent Developments/Updates
7.13.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.14 Pfizer
7.14.1 Pfizer Details
7.14.2 Pfizer Major Business
7.14.3 Pfizer Monoclonal Antibody Drugs for Cancer Product and Services
7.14.4 Pfizer Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Pfizer Recent Developments/Updates
7.14.6 Pfizer Competitive Strengths & Weaknesses
7.15 Regeneron
7.15.1 Regeneron Details
7.15.2 Regeneron Major Business
7.15.3 Regeneron Monoclonal Antibody Drugs for Cancer Product and Services
7.15.4 Regeneron Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Regeneron Recent Developments/Updates
7.15.6 Regeneron Competitive Strengths & Weaknesses
7.16 Innovent
7.16.1 Innovent Details
7.16.2 Innovent Major Business
7.16.3 Innovent Monoclonal Antibody Drugs for Cancer Product and Services
7.16.4 Innovent Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Innovent Recent Developments/Updates
7.16.6 Innovent Competitive Strengths & Weaknesses
7.17 Hengrui Medicine
7.17.1 Hengrui Medicine Details
7.17.2 Hengrui Medicine Major Business
7.17.3 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product and Services
7.17.4 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Hengrui Medicine Recent Developments/Updates
7.17.6 Hengrui Medicine Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Monoclonal Antibody Drugs for Cancer Industry Chain
8.2 Monoclonal Antibody Drugs for Cancer Upstream Analysis
8.3 Monoclonal Antibody Drugs for Cancer Midstream Analysis
8.4 Monoclonal Antibody Drugs for Cancer Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Monoclonal Antibody Drugs for Cancer Introduction
1.2 World Monoclonal Antibody Drugs for Cancer Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Monoclonal Antibody Drugs for Cancer Total Market by Region (by Headquarter Location)
1.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.3 China Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.4 Europe Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.5 Japan Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.6 South Korea Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.7 ASEAN Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.3.8 India Monoclonal Antibody Drugs for Cancer Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Monoclonal Antibody Drugs for Cancer Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Monoclonal Antibody Drugs for Cancer Major Market Trends
2 DEMAND SUMMARY
2.1 World Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.2 World Monoclonal Antibody Drugs for Cancer Consumption Value by Region
2.2.1 World Monoclonal Antibody Drugs for Cancer Consumption Value by Region (2018-2023)
2.2.2 World Monoclonal Antibody Drugs for Cancer Consumption Value Forecast by Region (2024-2029)
2.3 United States Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.4 China Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.5 Europe Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.6 Japan Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.7 South Korea Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.8 ASEAN Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
2.9 India Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029)
3 WORLD MONOCLONAL ANTIBODY DRUGS FOR CANCER COMPANIES COMPETITIVE ANALYSIS
3.1 World Monoclonal Antibody Drugs for Cancer Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Monoclonal Antibody Drugs for Cancer Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Monoclonal Antibody Drugs for Cancer in 2022
3.2.3 Global Concentration Ratios (CR8) for Monoclonal Antibody Drugs for Cancer in 2022
3.3 Monoclonal Antibody Drugs for Cancer Company Evaluation Quadrant
3.4 Monoclonal Antibody Drugs for Cancer Market: Overall Company Footprint Analysis
3.4.1 Monoclonal Antibody Drugs for Cancer Market: Region Footprint
3.4.2 Monoclonal Antibody Drugs for Cancer Market: Company Product Type Footprint
3.4.3 Monoclonal Antibody Drugs for Cancer Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Monoclonal Antibody Drugs for Cancer Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Monoclonal Antibody Drugs for Cancer Consumption Value Comparison
4.2.1 United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Monoclonal Antibody Drugs for Cancer Companies and Market Share, 2018-2023
4.3.1 United States Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
4.4 China Based Companies Monoclonal Antibody Drugs for Cancer Revenue and Market Share, 2018-2023
4.4.1 China Based Monoclonal Antibody Drugs for Cancer Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
4.5 Rest of World Based Monoclonal Antibody Drugs for Cancer Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Monoclonal Antibody Drugs for Cancer Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Mouse-derived Antibodies
5.2.2 Chimeric Antibodies
5.2.3 Humanized Antibodies
5.3 Market Segment by Type
5.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Type (2018-2023)
5.3.2 World Monoclonal Antibody Drugs for Cancer Market Size by Type (2024-2029)
5.3.3 World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Monoclonal Antibody Drugs for Cancer Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Lung Cancer
6.2.2 Breast Cancer
6.2.3 Prostate Cancer
6.2.4 Blood-related Cancer
6.2.5 Blood-related Cancer
6.3 Market Segment by Application
6.3.1 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2023)
6.3.2 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2024-2029)
6.3.3 World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Details
7.1.2 Johnson & Johnson Major Business
7.1.3 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product and Services
7.1.4 Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Johnson & Johnson Recent Developments/Updates
7.1.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Monoclonal Antibody Drugs for Cancer Product and Services
7.2.4 Novartis Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Gilead Sciences
7.3.1 Gilead Sciences Details
7.3.2 Gilead Sciences Major Business
7.3.3 Gilead Sciences Monoclonal Antibody Drugs for Cancer Product and Services
7.3.4 Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Gilead Sciences Recent Developments/Updates
7.3.6 Gilead Sciences Competitive Strengths & Weaknesses
7.4 Roche
7.4.1 Roche Details
7.4.2 Roche Major Business
7.4.3 Roche Monoclonal Antibody Drugs for Cancer Product and Services
7.4.4 Roche Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Roche Recent Developments/Updates
7.4.6 Roche Competitive Strengths & Weaknesses
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Details
7.5.2 Bristol-Myers Squibb Major Business
7.5.3 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product and Services
7.5.4 Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Bristol-Myers Squibb Recent Developments/Updates
7.5.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.6 Amgen
7.6.1 Amgen Details
7.6.2 Amgen Major Business
7.6.3 Amgen Monoclonal Antibody Drugs for Cancer Product and Services
7.6.4 Amgen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Amgen Recent Developments/Updates
7.6.6 Amgen Competitive Strengths & Weaknesses
7.7 AstraZeneca
7.7.1 AstraZeneca Details
7.7.2 AstraZeneca Major Business
7.7.3 AstraZeneca Monoclonal Antibody Drugs for Cancer Product and Services
7.7.4 AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 AstraZeneca Recent Developments/Updates
7.7.6 AstraZeneca Competitive Strengths & Weaknesses
7.8 Merck & Co
7.8.1 Merck & Co Details
7.8.2 Merck & Co Major Business
7.8.3 Merck & Co Monoclonal Antibody Drugs for Cancer Product and Services
7.8.4 Merck & Co Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Merck & Co Recent Developments/Updates
7.8.6 Merck & Co Competitive Strengths & Weaknesses
7.9 Takeda
7.9.1 Takeda Details
7.9.2 Takeda Major Business
7.9.3 Takeda Monoclonal Antibody Drugs for Cancer Product and Services
7.9.4 Takeda Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Takeda Recent Developments/Updates
7.9.6 Takeda Competitive Strengths & Weaknesses
7.10 Merck KGaA
7.10.1 Merck KGaA Details
7.10.2 Merck KGaA Major Business
7.10.3 Merck KGaA Monoclonal Antibody Drugs for Cancer Product and Services
7.10.4 Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Merck KGaA Recent Developments/Updates
7.10.6 Merck KGaA Competitive Strengths & Weaknesses
7.11 Seagen
7.11.1 Seagen Details
7.11.2 Seagen Major Business
7.11.3 Seagen Monoclonal Antibody Drugs for Cancer Product and Services
7.11.4 Seagen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Seagen Recent Developments/Updates
7.11.6 Seagen Competitive Strengths & Weaknesses
7.12 Eli Lilly
7.12.1 Eli Lilly Details
7.12.2 Eli Lilly Major Business
7.12.3 Eli Lilly Monoclonal Antibody Drugs for Cancer Product and Services
7.12.4 Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Eli Lilly Recent Developments/Updates
7.12.6 Eli Lilly Competitive Strengths & Weaknesses
7.13 Ono Pharmaceutical
7.13.1 Ono Pharmaceutical Details
7.13.2 Ono Pharmaceutical Major Business
7.13.3 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product and Services
7.13.4 Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Ono Pharmaceutical Recent Developments/Updates
7.13.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.14 Pfizer
7.14.1 Pfizer Details
7.14.2 Pfizer Major Business
7.14.3 Pfizer Monoclonal Antibody Drugs for Cancer Product and Services
7.14.4 Pfizer Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Pfizer Recent Developments/Updates
7.14.6 Pfizer Competitive Strengths & Weaknesses
7.15 Regeneron
7.15.1 Regeneron Details
7.15.2 Regeneron Major Business
7.15.3 Regeneron Monoclonal Antibody Drugs for Cancer Product and Services
7.15.4 Regeneron Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Regeneron Recent Developments/Updates
7.15.6 Regeneron Competitive Strengths & Weaknesses
7.16 Innovent
7.16.1 Innovent Details
7.16.2 Innovent Major Business
7.16.3 Innovent Monoclonal Antibody Drugs for Cancer Product and Services
7.16.4 Innovent Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Innovent Recent Developments/Updates
7.16.6 Innovent Competitive Strengths & Weaknesses
7.17 Hengrui Medicine
7.17.1 Hengrui Medicine Details
7.17.2 Hengrui Medicine Major Business
7.17.3 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product and Services
7.17.4 Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Hengrui Medicine Recent Developments/Updates
7.17.6 Hengrui Medicine Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Monoclonal Antibody Drugs for Cancer Industry Chain
8.2 Monoclonal Antibody Drugs for Cancer Upstream Analysis
8.3 Monoclonal Antibody Drugs for Cancer Midstream Analysis
8.4 Monoclonal Antibody Drugs for Cancer Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Monoclonal Antibody Drugs for Cancer Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Monoclonal Antibody Drugs for Cancer Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Monoclonal Antibody Drugs for Cancer Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Monoclonal Antibody Drugs for Cancer Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Monoclonal Antibody Drugs for Cancer Players in 2022
Table 12. World Monoclonal Antibody Drugs for Cancer Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Monoclonal Antibody Drugs for Cancer Company Evaluation Quadrant
Table 14. Head Office of Key Monoclonal Antibody Drugs for Cancer Player
Table 15. Monoclonal Antibody Drugs for Cancer Market: Company Product Type Footprint
Table 16. Monoclonal Antibody Drugs for Cancer Market: Company Product Application Footprint
Table 17. Monoclonal Antibody Drugs for Cancer Mergers & Acquisitions Activity
Table 18. United States VS China Monoclonal Antibody Drugs for Cancer Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Monoclonal Antibody Drugs for Cancer Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
Table 21. United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 23. China Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (Province, Country)
Table 24. China Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 26. Rest of World Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 29. World Monoclonal Antibody Drugs for Cancer Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Monoclonal Antibody Drugs for Cancer Market Size by Type (2018-2023) & (USD Million)
Table 31. World Monoclonal Antibody Drugs for Cancer Market Size by Type (2024-2029) & (USD Million)
Table 32. World Monoclonal Antibody Drugs for Cancer Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2023) & (USD Million)
Table 34. World Monoclonal Antibody Drugs for Cancer Market Size by Application (2024-2029) & (USD Million)
Table 35. Johnson & Johnson Basic Information, Area Served and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product and Services
Table 38. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Johnson & Johnson Recent Developments/Updates
Table 40. Johnson & Johnson Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Monoclonal Antibody Drugs for Cancer Product and Services
Table 44. Novartis Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Gilead Sciences Basic Information, Area Served and Competitors
Table 48. Gilead Sciences Major Business
Table 49. Gilead Sciences Monoclonal Antibody Drugs for Cancer Product and Services
Table 50. Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Gilead Sciences Recent Developments/Updates
Table 52. Gilead Sciences Competitive Strengths & Weaknesses
Table 53. Roche Basic Information, Area Served and Competitors
Table 54. Roche Major Business
Table 55. Roche Monoclonal Antibody Drugs for Cancer Product and Services
Table 56. Roche Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Roche Recent Developments/Updates
Table 58. Roche Competitive Strengths & Weaknesses
Table 59. Bristol-Myers Squibb Basic Information, Area Served and Competitors
Table 60. Bristol-Myers Squibb Major Business
Table 61. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product and Services
Table 62. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bristol-Myers Squibb Recent Developments/Updates
Table 64. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 65. Amgen Basic Information, Area Served and Competitors
Table 66. Amgen Major Business
Table 67. Amgen Monoclonal Antibody Drugs for Cancer Product and Services
Table 68. Amgen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Amgen Recent Developments/Updates
Table 70. Amgen Competitive Strengths & Weaknesses
Table 71. AstraZeneca Basic Information, Area Served and Competitors
Table 72. AstraZeneca Major Business
Table 73. AstraZeneca Monoclonal Antibody Drugs for Cancer Product and Services
Table 74. AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. AstraZeneca Recent Developments/Updates
Table 76. AstraZeneca Competitive Strengths & Weaknesses
Table 77. Merck & Co Basic Information, Area Served and Competitors
Table 78. Merck & Co Major Business
Table 79. Merck & Co Monoclonal Antibody Drugs for Cancer Product and Services
Table 80. Merck & Co Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Merck & Co Recent Developments/Updates
Table 82. Merck & Co Competitive Strengths & Weaknesses
Table 83. Takeda Basic Information, Area Served and Competitors
Table 84. Takeda Major Business
Table 85. Takeda Monoclonal Antibody Drugs for Cancer Product and Services
Table 86. Takeda Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Takeda Recent Developments/Updates
Table 88. Takeda Competitive Strengths & Weaknesses
Table 89. Merck KGaA Basic Information, Area Served and Competitors
Table 90. Merck KGaA Major Business
Table 91. Merck KGaA Monoclonal Antibody Drugs for Cancer Product and Services
Table 92. Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Merck KGaA Recent Developments/Updates
Table 94. Merck KGaA Competitive Strengths & Weaknesses
Table 95. Seagen Basic Information, Area Served and Competitors
Table 96. Seagen Major Business
Table 97. Seagen Monoclonal Antibody Drugs for Cancer Product and Services
Table 98. Seagen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Seagen Recent Developments/Updates
Table 100. Seagen Competitive Strengths & Weaknesses
Table 101. Eli Lilly Basic Information, Area Served and Competitors
Table 102. Eli Lilly Major Business
Table 103. Eli Lilly Monoclonal Antibody Drugs for Cancer Product and Services
Table 104. Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Eli Lilly Recent Developments/Updates
Table 106. Eli Lilly Competitive Strengths & Weaknesses
Table 107. Ono Pharmaceutical Basic Information, Area Served and Competitors
Table 108. Ono Pharmaceutical Major Business
Table 109. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product and Services
Table 110. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Ono Pharmaceutical Recent Developments/Updates
Table 112. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 113. Pfizer Basic Information, Area Served and Competitors
Table 114. Pfizer Major Business
Table 115. Pfizer Monoclonal Antibody Drugs for Cancer Product and Services
Table 116. Pfizer Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Pfizer Recent Developments/Updates
Table 118. Pfizer Competitive Strengths & Weaknesses
Table 119. Regeneron Basic Information, Area Served and Competitors
Table 120. Regeneron Major Business
Table 121. Regeneron Monoclonal Antibody Drugs for Cancer Product and Services
Table 122. Regeneron Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Regeneron Recent Developments/Updates
Table 124. Regeneron Competitive Strengths & Weaknesses
Table 125. Innovent Basic Information, Area Served and Competitors
Table 126. Innovent Major Business
Table 127. Innovent Monoclonal Antibody Drugs for Cancer Product and Services
Table 128. Innovent Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Innovent Recent Developments/Updates
Table 130. Hengrui Medicine Basic Information, Area Served and Competitors
Table 131. Hengrui Medicine Major Business
Table 132. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product and Services
Table 133. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 134. Global Key Players of Monoclonal Antibody Drugs for Cancer Upstream (Raw Materials)
Table 135. Monoclonal Antibody Drugs for Cancer Typical Customers
LIST OF FIGURE
Figure 1. Monoclonal Antibody Drugs for Cancer Picture
Figure 2. World Monoclonal Antibody Drugs for Cancer Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Monoclonal Antibody Drugs for Cancer Total Market Size (2018-2029) & (USD Million)
Figure 4. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 13. Monoclonal Antibody Drugs for Cancer Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 16. World Monoclonal Antibody Drugs for Cancer Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 18. China Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 23. India Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Monoclonal Antibody Drugs for Cancer by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Monoclonal Antibody Drugs for Cancer Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Monoclonal Antibody Drugs for Cancer Markets in 2022
Figure 27. United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Monoclonal Antibody Drugs for Cancer Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type in 2022
Figure 31. Mouse-derived Antibodies
Figure 32. Chimeric Antibodies
Figure 33. Humanized Antibodies
Figure 34. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2018-2029)
Figure 35. World Monoclonal Antibody Drugs for Cancer Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application in 2022
Figure 37. Lung Cancer
Figure 38. Breast Cancer
Figure 39. Prostate Cancer
Figure 40. Blood-related Cancer
Figure 41. Other
Figure 42. Monoclonal Antibody Drugs for Cancer Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
Table 1. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Monoclonal Antibody Drugs for Cancer Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Monoclonal Antibody Drugs for Cancer Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Monoclonal Antibody Drugs for Cancer Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Monoclonal Antibody Drugs for Cancer Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Monoclonal Antibody Drugs for Cancer Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Monoclonal Antibody Drugs for Cancer Players in 2022
Table 12. World Monoclonal Antibody Drugs for Cancer Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Monoclonal Antibody Drugs for Cancer Company Evaluation Quadrant
Table 14. Head Office of Key Monoclonal Antibody Drugs for Cancer Player
Table 15. Monoclonal Antibody Drugs for Cancer Market: Company Product Type Footprint
Table 16. Monoclonal Antibody Drugs for Cancer Market: Company Product Application Footprint
Table 17. Monoclonal Antibody Drugs for Cancer Mergers & Acquisitions Activity
Table 18. United States VS China Monoclonal Antibody Drugs for Cancer Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Monoclonal Antibody Drugs for Cancer Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
Table 21. United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 23. China Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (Province, Country)
Table 24. China Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 26. Rest of World Based Monoclonal Antibody Drugs for Cancer Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Monoclonal Antibody Drugs for Cancer Revenue Market Share (2018-2023)
Table 29. World Monoclonal Antibody Drugs for Cancer Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Monoclonal Antibody Drugs for Cancer Market Size by Type (2018-2023) & (USD Million)
Table 31. World Monoclonal Antibody Drugs for Cancer Market Size by Type (2024-2029) & (USD Million)
Table 32. World Monoclonal Antibody Drugs for Cancer Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Monoclonal Antibody Drugs for Cancer Market Size by Application (2018-2023) & (USD Million)
Table 34. World Monoclonal Antibody Drugs for Cancer Market Size by Application (2024-2029) & (USD Million)
Table 35. Johnson & Johnson Basic Information, Area Served and Competitors
Table 36. Johnson & Johnson Major Business
Table 37. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Product and Services
Table 38. Johnson & Johnson Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Johnson & Johnson Recent Developments/Updates
Table 40. Johnson & Johnson Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Monoclonal Antibody Drugs for Cancer Product and Services
Table 44. Novartis Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Gilead Sciences Basic Information, Area Served and Competitors
Table 48. Gilead Sciences Major Business
Table 49. Gilead Sciences Monoclonal Antibody Drugs for Cancer Product and Services
Table 50. Gilead Sciences Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Gilead Sciences Recent Developments/Updates
Table 52. Gilead Sciences Competitive Strengths & Weaknesses
Table 53. Roche Basic Information, Area Served and Competitors
Table 54. Roche Major Business
Table 55. Roche Monoclonal Antibody Drugs for Cancer Product and Services
Table 56. Roche Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Roche Recent Developments/Updates
Table 58. Roche Competitive Strengths & Weaknesses
Table 59. Bristol-Myers Squibb Basic Information, Area Served and Competitors
Table 60. Bristol-Myers Squibb Major Business
Table 61. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Product and Services
Table 62. Bristol-Myers Squibb Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Bristol-Myers Squibb Recent Developments/Updates
Table 64. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 65. Amgen Basic Information, Area Served and Competitors
Table 66. Amgen Major Business
Table 67. Amgen Monoclonal Antibody Drugs for Cancer Product and Services
Table 68. Amgen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Amgen Recent Developments/Updates
Table 70. Amgen Competitive Strengths & Weaknesses
Table 71. AstraZeneca Basic Information, Area Served and Competitors
Table 72. AstraZeneca Major Business
Table 73. AstraZeneca Monoclonal Antibody Drugs for Cancer Product and Services
Table 74. AstraZeneca Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. AstraZeneca Recent Developments/Updates
Table 76. AstraZeneca Competitive Strengths & Weaknesses
Table 77. Merck & Co Basic Information, Area Served and Competitors
Table 78. Merck & Co Major Business
Table 79. Merck & Co Monoclonal Antibody Drugs for Cancer Product and Services
Table 80. Merck & Co Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Merck & Co Recent Developments/Updates
Table 82. Merck & Co Competitive Strengths & Weaknesses
Table 83. Takeda Basic Information, Area Served and Competitors
Table 84. Takeda Major Business
Table 85. Takeda Monoclonal Antibody Drugs for Cancer Product and Services
Table 86. Takeda Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Takeda Recent Developments/Updates
Table 88. Takeda Competitive Strengths & Weaknesses
Table 89. Merck KGaA Basic Information, Area Served and Competitors
Table 90. Merck KGaA Major Business
Table 91. Merck KGaA Monoclonal Antibody Drugs for Cancer Product and Services
Table 92. Merck KGaA Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Merck KGaA Recent Developments/Updates
Table 94. Merck KGaA Competitive Strengths & Weaknesses
Table 95. Seagen Basic Information, Area Served and Competitors
Table 96. Seagen Major Business
Table 97. Seagen Monoclonal Antibody Drugs for Cancer Product and Services
Table 98. Seagen Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Seagen Recent Developments/Updates
Table 100. Seagen Competitive Strengths & Weaknesses
Table 101. Eli Lilly Basic Information, Area Served and Competitors
Table 102. Eli Lilly Major Business
Table 103. Eli Lilly Monoclonal Antibody Drugs for Cancer Product and Services
Table 104. Eli Lilly Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Eli Lilly Recent Developments/Updates
Table 106. Eli Lilly Competitive Strengths & Weaknesses
Table 107. Ono Pharmaceutical Basic Information, Area Served and Competitors
Table 108. Ono Pharmaceutical Major Business
Table 109. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Product and Services
Table 110. Ono Pharmaceutical Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Ono Pharmaceutical Recent Developments/Updates
Table 112. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 113. Pfizer Basic Information, Area Served and Competitors
Table 114. Pfizer Major Business
Table 115. Pfizer Monoclonal Antibody Drugs for Cancer Product and Services
Table 116. Pfizer Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Pfizer Recent Developments/Updates
Table 118. Pfizer Competitive Strengths & Weaknesses
Table 119. Regeneron Basic Information, Area Served and Competitors
Table 120. Regeneron Major Business
Table 121. Regeneron Monoclonal Antibody Drugs for Cancer Product and Services
Table 122. Regeneron Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Regeneron Recent Developments/Updates
Table 124. Regeneron Competitive Strengths & Weaknesses
Table 125. Innovent Basic Information, Area Served and Competitors
Table 126. Innovent Major Business
Table 127. Innovent Monoclonal Antibody Drugs for Cancer Product and Services
Table 128. Innovent Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Innovent Recent Developments/Updates
Table 130. Hengrui Medicine Basic Information, Area Served and Competitors
Table 131. Hengrui Medicine Major Business
Table 132. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Product and Services
Table 133. Hengrui Medicine Monoclonal Antibody Drugs for Cancer Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 134. Global Key Players of Monoclonal Antibody Drugs for Cancer Upstream (Raw Materials)
Table 135. Monoclonal Antibody Drugs for Cancer Typical Customers
LIST OF FIGURE
Figure 1. Monoclonal Antibody Drugs for Cancer Picture
Figure 2. World Monoclonal Antibody Drugs for Cancer Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Monoclonal Antibody Drugs for Cancer Total Market Size (2018-2029) & (USD Million)
Figure 4. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Monoclonal Antibody Drugs for Cancer Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Monoclonal Antibody Drugs for Cancer Revenue (2018-2029) & (USD Million)
Figure 13. Monoclonal Antibody Drugs for Cancer Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 16. World Monoclonal Antibody Drugs for Cancer Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 18. China Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 23. India Monoclonal Antibody Drugs for Cancer Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Monoclonal Antibody Drugs for Cancer by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Monoclonal Antibody Drugs for Cancer Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Monoclonal Antibody Drugs for Cancer Markets in 2022
Figure 27. United States VS China: Monoclonal Antibody Drugs for Cancer Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Monoclonal Antibody Drugs for Cancer Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Monoclonal Antibody Drugs for Cancer Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type in 2022
Figure 31. Mouse-derived Antibodies
Figure 32. Chimeric Antibodies
Figure 33. Humanized Antibodies
Figure 34. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Type (2018-2029)
Figure 35. World Monoclonal Antibody Drugs for Cancer Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Monoclonal Antibody Drugs for Cancer Market Size Market Share by Application in 2022
Figure 37. Lung Cancer
Figure 38. Breast Cancer
Figure 39. Prostate Cancer
Figure 40. Blood-related Cancer
Figure 41. Other
Figure 42. Monoclonal Antibody Drugs for Cancer Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
